Evaluation of the safety and efficacy of TRC003 in metastatic triple-negative breast cancer: A prospective, open-label, multicenter, single-arm exploratory clinical trial
Abstract
TPS1161
Background:
TRC003 (also named
225
Ac-TR2205) is a novel molecule of targeted alpha therapy (TAT) designed to deliver alpha-particle radiation to cancer cells expressing prostate-specific membrane antigen (PSMA). Compared to beta-particles, alpha-particles have a shorter path length and higher linear energy transfer, resulting in more frequent double-strand DNA breaks and potentially superior antitumor efficacy. In an ongoing pilot study, TRC003 has demonstrated a favorable safety profile and promising activity in patients with prostate cancer. Notably, PSMA expression has been reported in up to 60% of breast cancer neovasculature, with the highest rates observed in triple-negative breast cancer (TNBC). A head-to-head study found valuable insights into the expression of PSMA in TNBC and underscore the potential clinical significance of PSMA PET/CT in enhancing both diagnostic and therapeutic approaches for TNBC. This study aims to investigate the preliminary safety and efficacy of
225
Ac-TRC003 in patients with metastatic TNBC (mTNBC).
Methods:
This is a prospective, open-label, multicenter, single-arm study in accordance with ICH GCP guidelines at two centers. The primary objective is to evaluate the safety and tolerability of TRC003. Secondary endpoints include Objective Response Rate (ORR), Disease Control Rate (DCR), Duration of Response (DoR), Time to Progression (TTP), progression-free survival (PFS) and overall survival (OS). Key eligibility criteria include:…
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.